Press release
Dementia test predicts disease 18 years before symptoms
The DST (Dementia Screening Test) is the only dementia test which has been accepted as a Medical Device by Health Authorities.
• Good therapy options exist for this pre-symptomatic phase.
It has been known for several years that cognitive tests can "predict" dementia 10-12 years prior to clinical symptoms - or more precisely: they can recognize initial limitations in people who are not clinically conspicuous / symptomatic in everyday life, but who are later diagnosed with dementia. The American "Rush Institute for Healthy Aging" has now shown in a prospective study of 2.125 participant that this is possible also 18 years before or even earlier.
The results extended the previously found period from 12 years to 18 years. In particular, it was shown that a loss of the so-called "executive functions" of the brain even often preceded the "memory loss", and therefore can be at least an equally good criterion for early detection. Therefore, multi-dimensional tests which test several different brain functions, including executive functions and memory, may be superior to one-dimensional tests in early detection.
"Executive functions" refers to those mental functions used by humans to control their own behavior. They serve to optimally adapt one's own actions to a situation. They are especially used when automated action is no longer sufficient for problem solving. Examples include correcting a mistake, learning a complicated new skill, or breaking deep-rooted habits. In these cases, instead of routine procedures, a high degree of conscious and attentive / planning / assessing actions are needed, for which executive functions are required.
Further research focusing on the temporal pattern of cognitive deficits leading up to dementia development and thus, on middle aged persons, could provide a better understanding of the preclinical stages of dementia. Similarly, preventive measures at this stage may be most effective in slowing down the manifestation of dementia, as there are no effective treatments for clinical / symptomatic stages, according to the authors of the study.
Kumar B. Rajan, Robert S. Wilson, Jennifer Weuve, Lisa L. Barnes, Denis A. Evans; American Academy of Neurology, 08 Sep 2015; 85 (10): “Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia”; doi: https://doi.org/10.1212/WNL.0000000000001774
The DST (Dementia Screening Test) has been developed by a group of physicians with the objective to detect Dementia and start with interventions early, at a stage for which good treatment options exist.
Sebastian Dr. Horn
Friedrichstr. 67
10117 Berlin, Germany
+49 152 55834551
horn@demenz-test.com
http://www.demenz-test.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dementia test predicts disease 18 years before symptoms here
News-ID: 1574699 • Views: …
More Releases from DST
Dementia screening and prevention – hope or hype?
It is estimated that about 50% of dementia patients do not receive a formal diagnosis. And when the diagnosis is made, it often happens at a time when the disease is well advanced and brain damages are irreversible.
A major reason for this is that systematic dementia screening and prevention programmes are not yet ready for implementation as large-scale public health interventions. A key reason for this is the desire…
Dementia begins in the mid-40s - early detection crucial
We know today that those who will probably be demented in 15 to 20 years are already experiencing their first brain changes today. In other words, in many people it is already clear at the age of 40 to 50 whether they start to develop dementia. Fortunately, our brain can compensate individual deficits so well for 15 to 20 years that the affected person and the environment do not notice…
Early Dementia detection via App receives medical device status
- The DST (Dementia Screening Test) App has been recognized by Health Authorities as a Medical Device.
- Early Dementia stages are reliably detected, before the brain damages become irreversible.
- Sensitivity above 96%, significantly higher than with the established tests (e.g., MMSE 71%).
Dementia is a rapidly increasing social problem of a rapidly aging society. Because until today, there is no effective therapy for advanced stages of dementia. Therefore, effective screening…
More Releases for Dementia
Dementia Care APP Market Is Booming Worldwide 2021-2027 | Dementia Digital Diary …
Global Dementia Care APP market 2020-2026 in-depth study accumulated to supply latest insights concerning acute options. The report contains different predictions associated with Dementia Care APP market size, revenue, production, CAGR, consumption, profit margin, price, and different substantial factors. Whereas accentuation the key driving and Dementia Care APP restraining forces for this market, the report offers trends and developments. It additionally examines the role of the leading…
Dementia screening and prevention – hope or hype?
It is estimated that about 50% of dementia patients do not receive a formal diagnosis. And when the diagnosis is made, it often happens at a time when the disease is well advanced and brain damages are irreversible.
A major reason for this is that systematic dementia screening and prevention programmes are not yet ready for implementation as large-scale public health interventions. A key reason for this is the desire…
Dementia Treatment
Dementia Drugs and Treatment Market describes its growth, size, share, Forecast and trends to 2025
The global Dementia Drugs and Treatment market is valued at 13900 million US$ in 2018 is expected to reach 26500 million US$ by the end of 2025, growing at a CAGR of 8.4% during 2019-2025.
This report focuses on Dementia Drugs volume and value at global level, regional level and company level. From a global perspective, this…
New App detects dementia risks early
• The App is certified as a Medical Device.
• Early stages are reliably detected, before the brain damage becomes irreversible.
• Sensitivity above 96%, significantly higher than with the established tests (e.g., MMSE 71%).
• Now available for free during pre-launch.
Dementia is a rapidly increasing social problem of a rapidly aging society. Because until today there is no effective therapy for advanced stages of dementia.
Therefore, effective screening tests are needed to detect early stages…
2nd International Conference on Dementia and Dementia Care
Breakthrough in Dementia Research and Care
Event Name: 2nd International Conference on Dementia and Dementia Care (Dementia 2019)
Theme: Breakthrough in Dementia Research and Care
Aim and Scope: Dementia is an umbrella term used to describe a set of symptoms that occur when the brain is affected by disease. There’s currently no cure and no treatment that slows or stops its progression, but there are things you can do to help reduce the…
11th International Conference on Vascular Dementia
Can We Cure Dementia, Vascular Dementia and Alzheimer's disease?
It’s our pleasure to invite all the participants from all over the world to attend the 11th International Conference on Vascular Dementia which is held during February 15-16, 2019 Amsterdam| Netherlands.
Vascular Dementia conference will assemble illustrious speakers, Researchers, Nobel laureates, Neurologists, and Neuroscience researchers from both academic and health care professionals will join this event to discuss their views and research. The…
